

Page 1 of 5

Attorney Docket No.
101765.00106 (2870/9)

10/7/5,852
Serial No.
~~TBA~~

Applicant(s): GETMAN et al.

Filing Date: November 19, 2003

Group:
~~TBA~~ 1626

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	AA	4,599,198	07/08/86	Hoover			
	AB	SIR H725	01/02/90	Gordon			
	AC	4,514,391	04/30/85	Gordon et al.			
	AD	4,450,164	04/30/85	Bristol et al.			
	AE	4,477,441	10/16/84	Boger et al.			
	AF	4,548,926	10/22/85	Matsueda et al.			
	AG	4,616,088	10/07/86	Ryono et al.			
	AH	4,668,769	05/26/87	Hoover			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	AI	0 346 847 A2	12/20/89	Europe				
	AJ	0 342 541 A2	11/23/89	Europe				
	AK	2,184,730 A	07/01/87	UK				
	AL	2,209,752 A	05/24/89	UK				
	AM	0 264 795 A2	04/27/88	Europe				
	AN	0 264 795 A3	04/27/88	Europe				
	AO	2,200,115 A	07/27/88	UK				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	AP	Roberts et al., "Rational Design of Peptide-Based HIV Proteinase Inhibitors", Science, 248, 358-361, (1990)
	AQ	Erickson et al., "Design, Activity, and 2.8 Å Crystal Structure of a C ₂ Symmetric Inhibitor Complexed to HIV-1 Protease", Science, 249, 527-533 (1990)
	AR	Pearle et al., Nature, International Weekly Journal of Science, Vol. 328, No. 6130, pg. 482, Aug. 6-12, (1987)

EXAMINER

DATE CONSIDERED

5/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office
**INFORMATION DISCLOSURE
CITATION**

Page 2 of 5

Attorney Docket No.
101765.00106 (2870/9)

10/15/82
Serial No.
~~484~~

Applicant(s): GETMAN et al.

Filing Date: November 19, 2003

Group: ~~484~~
1626

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclasses	Filing Date (if appropriate)
	BA	4,668,770	05/26/87	Boger et al.			
	BB	4,757,050	07/12/88	Natarajan et al.			
	BC	4,880,938	11/14/89	Freidinger			
	BD	4,963,530	10/16/90	Hemmi et al.			
	BE	4,977,277	12/11/90	Rosenberg et al.			
	BF	4,595,407	06/17/86	L. Carter			
	BG	4,634,465	01/06/87	Ehrenfreund et al.			
	BH	5,776,971	07/07/98	Getman et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclasses	Translation	
							YES	NO
	BI	WO 93/13066	07/08/93	PCT				
	BJ	0 114 993 A2	08/08/84	Europe				
	BK	0 172 347 A2	02/26/86	Europe				
	BL	0 223 437 A2	05/27/87	Europe				
	BM	0 337 714 A2	10/18/89	Europe				
	BN	0 356 223 A2	02/28/90	Europe				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	BO	Martin, "Ro 31-8959/003", Drugs of the Future, 16 (3), 210-212 (1991)
	BP	Meek et al., "Inhibition of HIV-1 Protease in Infected T-lymphocytes by Synthetic Peptide Analogues", Nature, Vol. 343, pp. 90-92 (1990)
	BQ	McQuade, "A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation", Science, Vol. 247, 454-456 (1990)

EXAMINER

DATE CONSIDERED

5/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office
**INFORMATION DISCLOSURE
CITATION**

Attorney Docket No.
101765.00106 (2870/9)

10/7/15, 852
Serial No.
~~FBA~~


Applicant(s): GETMAN et al.

Filing Date: November 19, 2003










Group: ~~FBA~~
1626

Page 3 of 5









U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	CA 5,278,148	01/11/94	Branca et al.	—	—	


FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	CB	0 389 898 A2	10/03/90	Europe				
	CC	PCT/US93/08458	03/17/94	PCT				
	CD	WO 94/05639	03/17/94	PCT				
	CE	0 393 445 A2	10/24/90	German				
	CF	0 393 457 A1	10/24/90	Europe				
	CG	0 402 646 A1	12/19/90	Europe				
	CH	AU-A-79823/87	04/28/88	Australia				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	CI	Rich et al., "Design of Protease Inhibitors", Peptide Inhibitors of Proteases, 511-520, 1983.
	CJ	Rosenberg et al., "Novel Renin Inhibitors Containing Analogues of Statine Retro-Inverted at the C-Termini: Specificity at the P ₂ Histidine Site", J. Med. Chem., 30, 1224-1228 (1987)
	CK	Fittkau, "α-Aminochloromethylketone aus Aminosäuren and Peptiden als substratanaloge Inhibitoren der Leucinaminopeptidase, Journal f. Prakt. Chemie., Band 315, Heft 6, S. 1037-1044 (1973)
	CL	Hirsch et al. "Therapy for Human Immunodeficiency Virus Infection", New England Journal of Medicine, Vol. 328, No. 23, 1686-1695 (1993)
	CM	E.E. Gilbert, "Recent Developments in Preparative Sulfonation and Sulfation", Synthesis, International Journal of Methods in Synthetic Organic Chemistry, No. 1: September (1969)
	CN	Mitsuya et al., "Inhibition of the <i>in vitro</i> Infectivity and Cytopathic Effect of Human T-lymphotrophic Virus Type III/Lymphadenopathy-Associated Cirus (HTLV-III/LAV) by 2',3'-Dideoxynulceosides", Prod. Natl. Acad. Sci. USA, Vol. 83, 1911-15 March (1986)
	CO	Silcox et al., "Benzodioxoles, Naphthodioxins and Dibenzodioxepins", J. Heterocycl. Chem., 4, 166-67 (1967)
	CP	Cabiddu et al., "A Convenient Method for the Synthesis of 1,3-Benzoxathioles", Synthesis, 797-798 (1976)

EXAMINER



DATE CONSIDERED

5/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

INFORMATION DISCLOSURE
CITATION

Page 4 of 5

Attorney Docket No.

101765.00106 (2870/9)

10/75,852
Serial No.

-FBA

Applicant(s): GETMAN et al.

Filing Date: November 19, 2003

Group: 1626

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
DA						
DB						


FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
DS	DC	0 468 641 A3	01/29/92	Europe				
DS	DD	WO 92/08699	05/29/92	PCT				
DS	DE	WO 94/04492	03/03/94	PCT				
DS	DF	WO 94/10134	05/11/94	PCT				
DS	DG	WO 95/06030	03/02/95	PCT				
DS	DH	WO 95/33464	12/14/95	PCT				
DS	DI	WO 94/10133	05/11/94	PCT				
DS	DJ	WO 84/03044	08/16/84	PCT				
DS	DK	0 104 041	03/28/84	Europe				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

DS	DL	International Search Report dated July 25, 1996 for application PCT/US96/02683					
DS	DM	Ncube et al., "Generation and Reactions of 2-Lithio-2-Substituted-1,3-Benzodithioles: New, Convenient Acyl Carbanion Equivalents", Tetrahedron Letters No. 26, 2345-2348 (1978)					
DS	DN	Ncube et al., "A Convenient Synthesis of 2-Alkyl- and 2-Aryl-1,3-Benzodithioles", Tetrahedron Letters No. 3, 255-256 (1977)					
DS	DO	Cole et al., "An Improved Method for the Synthesis of 2,2-Disubstituted and 2-Monosubstituted 1,3-Benzodioxoles", Aust. J. Chem., 33, 675-80 (1980)					

EXAMINER



DATE CONSIDERED

5/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	FOIA 101715852
				Filing Date	November 19, 2003
				First Named Inventor	Daniel P. Getman, et al.
				Group Art Unit	FOIA 1626
				Examiner Name	FOIA Stockton
				Attorney Docket Number	101765.00106 (2870/9)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>Lam S. Stockton</i>	Date Considered	5/2/05
-----------------------	------------------------	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
do not respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/715,852
Filing Date	November 19, 2003
First Named Inventor	Daniel P. Getman
Art Unit	1626
Examiner Name	TBA <i>Stark</i>
Attorney Docket Number	101765.00106 (287)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.